pediatric ADHD

A child using a pre-commercial version of Akili's product.
By  Dave Muoio 03:07 pm March 29, 2021
Akili Interactive has published the full data from its STARS-ADHD Adjunctive trial. The data builds upon the company's pivotal study of AKL-T01 (now available as EndeavorRx) and suggests the videogame-like digital therapeutic delivers benefits with or without accompanying stimulant medication, and that they persist up to one month following the treatment. "These results increase the...
By  Dave Muoio 07:50 pm February 24, 2020
A full transcript of STARS-ADHD — the pivotal trial of Akili Interactive’s video game-like pediatric attention deficit treatment — has been published in The Lancet Digital Health journal, providing onlookers a clear view of data fueling the digital therapeutic company’s pending FDA submission. The writeup echoes topline findings first unveiled by the company in December 2017: compared to a...
By  Dave Muoio 02:00 pm January 15, 2020
Editor's note: The original version of this story claimed that STARS-ADHD Adjunctive enrolled 2016 subjects, instead of 206. We apologize for this error. Digital therapeutic company Akili Interactive has announced the first results of an open-label, multisite pediatric ADHD trial providing some patients with the company’s video game-like treatment alongside a stimulant medication. Called the ...